B6E Stock Overview
A biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for B6E from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 26.92 |
| 52 Week High | SEK 30.50 |
| 52 Week Low | SEK 22.40 |
| Beta | 0.26 |
| 1 Month Change | 12.64% |
| 3 Month Change | -7.93% |
| 1 Year Change | 12.82% |
| 3 Year Change | 42.47% |
| 5 Year Change | 41.39% |
| Change since IPO | 126.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| B6E | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.8% | 0.6% | 1.7% |
| 1Y | 12.8% | -12.2% | 12.8% |
Return vs Industry: B6E exceeded the German Biotechs industry which returned -13.8% over the past year.
Return vs Market: B6E matched the German Market which returned 13.4% over the past year.
Price Volatility
| B6E volatility | |
|---|---|
| B6E Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: B6E has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: B6E's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,895 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| B6E fundamental statistics | |
|---|---|
| Market cap | €9.34b |
| Earnings (TTM) | €362.53m |
| Revenue (TTM) | €2.40b |
25.8x
P/E Ratio3.9x
P/S RatioIs B6E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B6E income statement (TTM) | |
|---|---|
| Revenue | SEK 26.24b |
| Cost of Revenue | SEK 5.69b |
| Gross Profit | SEK 20.54b |
| Other Expenses | SEK 16.58b |
| Earnings | SEK 3.96b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 16, 2025
| Earnings per share (EPS) | 11.53 |
| Gross Margin | 78.30% |
| Net Profit Margin | 15.09% |
| Debt/Equity Ratio | 35.0% |
How did B6E perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 15:45 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Xue Chen | Barclays |
| Rosie Turner | Barclays |